EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome

Kate Smith-Jackson, Patrick Walsh, Wioleta M Zelek, Thomas Hoyler, Marianne M Martinic, Gemma Thompson, Beth G Gibson, Chloe Connelly, Isabel Y Pappworth, Mark J Murphy, David Kavanagh, Kevin J Marchbank

Kidney International · 2025

DOI: 10.1016/j.kint.2024.12.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2025. Verfasst von Kate Smith-Jackson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Complement Therapeutics Research Group, Newcastle University Translational and Clinical Research Institute, the Medical School, Newcastle-upon-Tyne, …. Hauptthemen laut MEDLINE: Atypical Hemolytic Uremic Syndrome, Complement Membrane Attack Complex, Thrombotic Microangiopathies, Kidney. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Idorsia Pharmaceuticals Ltd, UK Research and Innovation Medical Research Council, Northern Counties Kidney Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mouse model, engineered around a gain of function point mutation in C3, is associated with complement mediated aHUS in man, allowing us to study the clinical disease in a preclinical model. Backcrossing our model onto C7 deficient and C5aR1 deficient mice enabled further determination of the roles of the C5a-C5aR1 axis and C5b-9 (the membrane attack complex) on kidney disease. C7 deficiency completely abolished both clinical and histological evidence of disease. Removing C5aR1 (CD88) attenuated the risk of developing clinical disease, but mice still developed thrombotic microangiopathy. Therapeutic inhibition strengthened our genetic findings showing both anti-C7 therapy and an oral C5aR1 antagonist, when used before evidence of significant kidney injury, prevented mice from succumbing to disease. However, there was ongoing histological disease within mice treated with the C5aR1 antagonist. Our data suggest that both C5aR1 and C7 play a role in the development of the conditions required for thrombotic microangiopathy of the kidney. While disrupting the C5a-C5aR1 axis is beneficial, our genetic and therapeutic studies showed that thrombotic microangiopathy of the kidney can still develop and ultimately our data confirm that the membrane attack complex is required to develop thrombotic microangiopathy of the kidney. Overall, our study shows that in addition to requiring alternative pathway dysregulation, local generation of membrane attack complex within the kidney is also critical to drive disease pathology in complement-mediated aHUS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atypical Hemolytic Uremic SyndromeComplement Membrane Attack ComplexThrombotic MicroangiopathiesKidneyAnimalsReceptor, Anaphylatoxin C5aDisease Models, AnimalMiceComplement C3Mice, KnockoutHumansComplement C5aMice, Inbred C57BLMaleComplement Inactivating AgentsComplement Activation

Stichwörter der Autor:innen

C3 gain-of-functionMACTMAaHUScomplementtherapy

Substanzen

Receptor, Anaphylatoxin C5aComplement Membrane Attack ComplexC5ar1 protein, mouseComplement C3Complement C5aComplement Inactivating Agents

Autor:innen und Institutionen

  • Complement Therapeutics Research Group, Newcastle University Translational and Clinical Research Institute, the Medical School, Newcastle-upon-Tyne, UK; National Renal Complement Therapeutics Centre, the Royal Victoria…
  • UK Dementia Research Institute Cardiff and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
  • Immunology and Oncology Biology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.

Förderung

  • Idorsia Pharmaceuticals Ltd
  • UK Research and Innovation Medical Research Council
  • Northern Counties Kidney Research Fund
  • Wellcome Trust
  • Catalyst Biosciences

Zitieren

APA

Smith-Jackson, K., Walsh, P., Zelek, W. M., Hoyler, T., Martinic, M. M., Thompson, G., Gibson, B. G., Connelly, C., Pappworth, I. Y., Murphy, M. J., Kavanagh, D., & Marchbank, K. J. (2025). The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International. https://doi.org/10.1016/j.kint.2024.12.016

Vancouver

Smith-Jackson K, Walsh P, Zelek WM, Hoyler T, Martinic MM, Thompson G, et al. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International. 2025. doi:10.1016/j.kint.2024.12.016

BibTeX
@article{SmithJackson2025,
  author = {Smith-Jackson, Kate and Walsh, Patrick and Zelek, Wioleta M and Hoyler, Thomas and Martinic, Marianne M and Thompson, Gemma and Gibson, Beth G and Connelly, Chloe and Pappworth, Isabel Y and Murphy, Mark J and Kavanagh, David and Marchbank, Kevin J},
  title = {The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome},
  journal = {Kidney International},
  year = {2025},
  doi = {10.1016/j.kint.2024.12.016}
}
Kostenlos starten →